Funded Biotechnology Startups in United States
In the 11 most recent disclosed rounds shown, the largest disclosed raise is Ollin Biosciences’ $330M Series B on 2026-06-24, which dwarfs every other disc…
In the 11 most recent disclosed rounds shown, the largest disclosed raise is Ollin Biosciences’ $330M Series B on 2026-06-24, which dwarfs every other disclosed amount in the list (the next-highest figures are $63M for AusperBio in 2025-09-28 and $50M for OncoC4 in 2025-10-05). Stage and geography cluster heavily: “Series Unknown” appears in 3 of the 11 entries (Dayra Therapeutics on 2025-11-26 for $20M; Oligon on 2025-09-22 for $14M; Enlaza Therapeutics on 2025-09-13 for $15M), while Cambridge shows up twice (Dayra Therapeutics on 2025-11-26 and AltrixBio on 2025-09-20), alongside repeated Southern California presence (San Diego, La Jolla, and nearby). Temporally, these rounds concentrate in a narrow late-September to late-November window—8 of 11 dates fall between 2025-09-13 and 2025-11-26—anchored by the newest 2026-06-24 round and the earliest among the visible rows, Chirality Biosciences on 2025-11-02 for $3M.
Most recent rounds
11 shownRelated listings
Frequently asked
Which recent disclosed round is the clear outlier, and how large is the gap versus the rest?
Ollin Biosciences’ $330M Series B on 2026-06-24 is an outlier: the next-highest disclosed rounds in the table are $63M (AusperBio on 2025-09-28) and $50M (OncoC4 on 2025-10-05).
Do these biotechnology/pharmaceutical rounds cluster more by time or by city?
Time is the stronger cluster: 8 of 11 rounds land between 2025-09-13 (Enlaza Therapeutics) and 2025-11-26 (Dayra Therapeutics). City clustering is present but lighter, with Cambridge appearing twice (Dayra Therapeutics on 2025-11-26 and AltrixBio on 2025-09-20).
How much of the list has an undisclosed round type, and which entries drive it?
3 of 11 entries are labeled “Venture - Series Unknown”: Dayra Therapeutics ($20M on 2025-11-26), Oligon ($14M on 2025-09-22), and Enlaza Therapeutics ($15M on 2025-09-13).
What stage mix dominates among the disclosed rounds shown?
If “Series Unknown” is excluded, the list is split across Series A, Series B, and Series C: Series B appears multiple times (Ollin Biosciences $330M on 2026-06-24; OncoC4 $50M on 2025-10-05; AusperBio $63M on 2025-09-28), while Series A also recurs (Bexorg $23M on 2025-10-19; AeroRx Therapeutics $21M on 2025-10-08).
Which dates represent the lower-end disclosed amounts, and what does that imply for negotiation tiers?
The smallest disclosed amount shown is Chirality Biosciences at $3M (Seed on 2025-11-02). Several other low entries sit near the $5M–$15M band (AltrixBio $5M on 2025-09-20; SelectION $5M on 2025-09-16; Enlaza Therapeutics $15M on 2025-09-13), suggesting a frequent mid-to-lower disclosed funding tier outside the $20M+ and above.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.